BRIEF-CSPC Pharmaceutical Obtains Clinical Trial Approval For SYS6043 (Antibody-Drug Conjugate) From NMPA

Reuters12-20
BRIEF-CSPC Pharmaceutical Obtains Clinical Trial Approval For SYS6043 (Antibody-Drug Conjugate) From NMPA

Dec 20 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:

  • SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL

  • APPROVAL FOR DRUG GRANTED BY NMPA

Further company coverage: 1093.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment